Profusa, Inc.

Profusa, Inc. (Nasdaq: PFSA) is a medical technology company developing implantable, continuous biosensor platforms designed to monitor body chemistry in real time, placing the firm within the broader digital health and bioelectronics sector. The company entered public markets via a SPAC transaction and filed its most recent Form 10-Q with the SEC on August 14, 2025 (accession no. 0001213900-25-076861), confirming its status as an active reporting company. Profusa's technology targets continuous physiological monitoring applications, distinguishing it from traditional discrete diagnostic devices. For full deal history, sponsor details, filing timelines, and analytics on PFSA and hundreds of other SPAC transactions, create a free account at SpacDesk.